TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 1-year incidence of biopsy-proven kidney or pancreas acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pancreas graft survival at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Drain volumes on the first and second postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor XIII plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-year complete success rate after trabeculectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for further hypotensive therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FABQ physical activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic diclofenac availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diclofenac penetration through the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild erythema at the application site
Endpoint domain: Adverse events/effects
Primary endpoint: Circulating CD4+CD25high+ regulatory T-cell level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recall rate at 7 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically unacceptable restorations due to loss of retention and severe marginal discoloration
Endpoint domain: Adverse events/effects
Primary endpoint: time required for patient instructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: test reliability as measured by the rate of fixation losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-linolenic acid content in human milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LA-ALA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete resolution of regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satisfactory resolution of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visual analog scores for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of nurse-controlled analgesia activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less intense pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in the quality of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm blood flow (FBF) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of stent-related bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postanesthesia shivering symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shivering score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet-induced thermogenesis (DIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensation of fullness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caloric compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean improvement in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of emesis-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of emesis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall response proportion (CRs plus PRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid retention
Endpoint domain: Adverse events/effects
Primary endpoint: Lowering of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in obesity-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vocabulary learning gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of skin prick tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of posttransplant diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total FAOS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating EPC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: β-index of the carotid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: urinary concentration of 8-isoprostane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: continuity of care after residential treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: treatment engagement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Minimum Alveolar Concentration (MAC) of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: linear growth velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' experience of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse coronary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean inter-proximal vertical bone defect fill at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Physician endorsement of the ACA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: RSS (Richmond Agitation-Sedation Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin action
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: endothelial-dependent vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood 25-hydroxycholecalciferol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant adherence to randomization assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of elbow flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensibility measured by Semmes‐Weinstein monofilaments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttest scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: clinical pigmentation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of pulmonary embolism (PE)
Endpoint domain: Mortality/survival
Primary endpoint: PE-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Sense of personal accomplishment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C max (Maximum Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t max (Time to Reach C max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline BCVA letter score at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HFS (Hand-Foot Syndrome)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: MACE free survival
Endpoint domain: Mortality/survival
Primary endpoint: leg wound pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound sepsis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perceived support for diagnosing mental health problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived ease of access to consultations for mental health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early skin toxicity (radiation dermatitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Breast infection
Endpoint domain: Adverse events/effects
Primary endpoint: cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: C-terminal telopeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Incidence of adverse events of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Induction conditions improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to normal sinus rhythm within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Calcidiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Willingness to donate blood
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Platelet response to ADP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in total posttraumatic severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endocrine-specific scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fatigue-specific score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Precision of measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: prolongation of exercise duration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean lead values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ADCS-CGI-C
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NPI apathy score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AES score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anhedonic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adherence to 4-weekly chemotherapy courses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hematologic side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Radiation exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of IgE antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of attempted assisted vaginal rotational delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: tissue damage measured with serum markers CK and CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular contrast enhancement uniformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total MPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: C(N) changes during trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histamine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tryptase release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vascular reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sensory effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidant-antioxidant levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite differences in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delta ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of talipes equinovarus
Endpoint domain: Adverse events/effects
Primary endpoint: Early, unintended pregnancy loss
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to ring use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent weight loss from baseline to week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast enhancement in the inferior vena cava
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast enhancement in pelvic vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sick leave duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day readmission rate after HF hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30-day readmission rate after all-cause hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average cost of herniorrhaphy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disability-adjusted life-years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the whole blood concentration-time curve of cyclosporine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration of cyclosporine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma glucagon levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intact GLP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in knowledge of geriatric medicine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduce symptoms of postnatal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Optimal dose of lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted complication score
Endpoint domain: Adverse events/effects
Primary endpoint: onsets of refractory angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: need for beta receptor blocker or calcium antagonists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain level (visual analog pain score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to work duration
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: DietSc improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained response at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ΔE values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS values
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of margin artifact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of uninterpretability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival without disability
Endpoint domain: Mortality/survival
Primary endpoint: mean total RQLQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: serum homocysteine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum estrone sulfate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 17beta-estradiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressiveness of cancers associated with IDC-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in exhaled carbon monoxide (CO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the PGI‐I scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intracellular fluid (ICF) volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Post-ERCP Pancreatitis (PEP)
Endpoint domain: Mortality/survival
Primary endpoint: Insulin sensitivity (K(itt) values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: treatment completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Geometric Mean Titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects positive for Neutralizing Antibodies (NAbs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICA wall volume regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to maximum motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery of motor block (Bromage score of zero)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of PAPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normalization of hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in pulmonary functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: self‐sedation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detection of amblyopiogenic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for detection of amblyopiogenic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term MACCE rate
Endpoint domain: Mortality/survival
Primary endpoint: basic arm functional tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with pain (PIPP score >6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective assessment of overall outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in axillary sweating at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of antiperspiration effect of BT-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSS scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total effective rate of pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for professional support during stroke adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of nateglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of diclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of treatments
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative urinary retention at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: patient encounters
Endpoint domain: Resource use
Endpoint subdomain: Other resource use